Literature DB >> 12120278

Therapeutic strategies for human amyloid diseases.

James C Sacchettini1, Jeffery W Kelly.   

Abstract

Amyloid diseases are a large group of a much larger family of misfolding diseases. This group includes pathologies as diverse as Alzheimer's disease, immunoglobulin-light-chain disease, reactive amyloid disease and the familial amyloid polyneuropathies. These diseases are generally incurable at present, although some drugs are known to transiently slow the progression of Alzheimer's disease. As we increase our understanding of the causative mechanisms of these disorders, the likelihood of success for a given therapeutic strategy will become clearer. This review will look at small-molecule and macromolecular approaches for intervention in amyloid diseases other than Alzheimer's disease, although select examples from Alzheimer's disease will be discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12120278     DOI: 10.1038/nrd769

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  59 in total

1.  Polyglutamine fibrillogenesis: the pathway unfolds.

Authors:  Christopher A Ross; Michelle A Poirier; Erich E Wanker; Mario Amzel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-30       Impact factor: 11.205

2.  Short amino acid stretches can mediate amyloid formation in globular proteins: the Src homology 3 (SH3) case.

Authors:  Salvador Ventura; Jesús Zurdo; Saravanakumar Narayanan; Matilde Parreño; Ramón Mangues; Bernd Reif; Fabrizio Chiti; Elisa Giannoni; Christopher M Dobson; Francesc X Aviles; Luis Serrano
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-03       Impact factor: 11.205

3.  Reversible aggregation plays a crucial role on the folding landscape of p53 core domain.

Authors:  Daniella Ishimaru; Luis M T R Lima; Lenize F Maia; Priscila M Lopez; Ana P Ano Bom; Ana P Valente; Jerson L Silva
Journal:  Biophys J       Date:  2004-08-06       Impact factor: 4.033

4.  Mass spectrometry and the amyloid problem--how far can we go in the gas phase?

Authors:  Alison E Ashcroft
Journal:  J Am Soc Mass Spectrom       Date:  2010-03-09       Impact factor: 3.109

5.  Protein-folding landscapes in multichain systems.

Authors:  Troy Cellmer; Dusan Bratko; John M Prausnitz; Harvey Blanch
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-04       Impact factor: 11.205

6.  Molecular alignment within beta-sheets in Abeta(14-23) fibrils: solid-state NMR experiments and theoretical predictions.

Authors:  Zimei Bu; Yuan Shi; David J E Callaway; Robert Tycko
Journal:  Biophys J       Date:  2006-10-20       Impact factor: 4.033

7.  A hydrophobic low-complexity region regulates aggregation of the yeast pyruvate kinase Cdc19 into amyloid-like aggregates in vitro.

Authors:  Erica Grignaschi; Gea Cereghetti; Fulvio Grigolato; Marie R G Kopp; Stefano Caimi; Lenka Faltova; Shady Saad; Matthias Peter; Paolo Arosio
Journal:  J Biol Chem       Date:  2018-05-31       Impact factor: 5.157

8.  A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.

Authors:  Sungwook Choi; Natàlia Reixach; Stephen Connelly; Steven M Johnson; Ian A Wilson; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2010-02-03       Impact factor: 15.419

9.  Inhibition of semen-derived enhancer of virus infection (SEVI) fibrillogenesis by zinc and copper.

Authors:  Sarah R Sheftic; Jessica M Snell; Suman Jha; Andrei T Alexandrescu
Journal:  Eur Biophys J       Date:  2012-08-21       Impact factor: 1.733

10.  Denaturation and solvent effect on the conformation and fibril formation of TGFBIp.

Authors:  Heather L Grothe; Morgan R Little; Angela S Cho; Andrew J W Huang; Ching Yuan
Journal:  Mol Vis       Date:  2009-12-08       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.